Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

NCT06958484 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma
Adjuvant Treatment

Interventions

DRUG: Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab

Sponsor

The Affiliated Hospital of Xuzhou Medical University